Accéder au contenu
Merck

Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity.

Nature immunology (2019-07-03)
Qingkun Liu, Emily M Johnson, Rachel K Lam, Qian Wang, Hong Bo Ye, Edward N Wilson, Paras S Minhas, Ling Liu, Michelle S Swarovski, Stephanie Tran, Jing Wang, Swapnil S Mehta, Xi Yang, Joshua D Rabinowitz, Samuel S Yang, Mehrdad Shamloo, Christoph Mueller, Michelle L James, Katrin I Andreasson
RÉSUMÉ

Stroke is a multiphasic process in which initial cerebral ischemia is followed by secondary injury from immune responses to ischemic brain components. Here we demonstrate that peripheral CD11b+CD45+ myeloid cells magnify stroke injury via activation of triggering receptor expressed on myeloid cells 1 (TREM1), an amplifier of proinflammatory innate immune responses. TREM1 was induced within hours after stroke peripherally in CD11b+CD45+ cells trafficking to ischemic brain. TREM1 inhibition genetically or pharmacologically improved outcome via protective antioxidant and anti-inflammatory mechanisms. Positron electron tomography imaging using radiolabeled antibody recognizing TREM1 revealed elevated TREM1 expression in spleen and, unexpectedly, in intestine. In the lamina propria, noradrenergic-dependent increases in gut permeability induced TREM1 on inflammatory Ly6C+MHCII+ macrophages, further increasing epithelial permeability and facilitating bacterial translocation across the gut barrier. Thus, following stroke, peripheral TREM1 induction amplifies proinflammatory responses to both brain-derived and intestinal-derived immunogenic components. Critically, targeting this specific innate immune pathway reduces cerebral injury.